Search
for
Did you mean EGFR inhibitors?
Sort by
Research 30 of 1000+
- Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors
- Persistent hair growth during treatment with the EGFR inhibitor erlotinib
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- Cutaneous side-effects of EGFR inhibitors and their management.
- Erosive Pustular Dermatosis of the Scalp-Like Eruption due to Gefitinib: Case Report and Review of the Literature of Alopecia Associated with EGFR Inhibitors
- The management of EGFR inhibitor adverse events: a case series and treatment paradigm
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Rash from EGFR inhibitors: Opportunities and challenges for palliation
- Network pharmacology-based preventive effect of XZF on cutaneous toxicities induced by EGFR inhibitor
- EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- 566 Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity
- PRIDE Complex (Papulopustules and/or Paronychia, Regulatory Abnormalities of Hair Growth, Itching, Dryness Due to EGFR Inhibitors)
- Folliculitis Decalvans-like Alopecia During Treatment With EGFR Inhibitors for Lung Cancer: A Case Series of 6 Patients
- Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR
- 422 Human hair follicles express PD-L1, whose expression is down-regulated by EGFR and MEK inhibitors ex vivo. A potential mechanism for EGFR inhibitor induced sterile folliculitis
- MARIO LACOUTURE: How Do I Treat a Patient with Dermatologic Toxicities to EGFR Inhibitors?
- Erosive pustular dermatosis of the scalp due to EGFR inhibitors: A multicentric study by EADV task force of ‘Dermatology for Cancer Patients’
- Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
- 861 EGFR/MEK inhibitor therapy induces partial hair follicle immune privilege collapse in vivo and ex vivo
- The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
- EGFR signaling is required for regenerative proliferation in the cochlea: Conservation in birds and mammals
- Dermatological side effects of epidermal growth factor receptor inhibitors: ′Pride′ complex
- A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib
- IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Treatment of Epidermal Growth Factor Receptor Inhibitor-Induced Acneiform Eruption with Topical Recombinant Human Epidermal Growth Factor
- Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?